Remdesivir cuts COVID-19 death risk by 62%, drugmaker sayshttps://www.upi.com/Health_News/2020/07/10/Remdesivir-cuts-COVID-19-death-risk-by-62-drugmaker-says/4861594386510/According to the data, remdesivir minimizes the risk of death by 62 percent in patients with the coronavirus, compared with standard care alone.
Gilead said the results came from a comparative analysis among 312 patients in its Phase 3 "SIMPLE-Severe" remdesivir clinical trial. Patients receiving the drug were compared to a "real-world" cohort of 818 COVID-19 patients with similar characteristics and disease severity who received only standard care.
Base on Gilead's press release,
https://www.gilead.com/news-and-press/press-room/press-releases/2020/7/gilead-presents-additional-data-on-investigational-antiviral-remdesivir-for-the-treatment-of-covid-19 , UPI was incorrect in saying, later in the article, that the tested patients had received 28 days of treatment with remdesivir. The test also tested across a wide degree of symptoms, which I (a non-medical person) think is not the best way to use the drug. It's an anti-viral, and probably should be used early, to hinder the virus' infection process early rather than late in the progress of infection.
